Table 2 Management and outcomes of critically ill COVID-19 patients (n = 566) during their intensive care unit stay according to Coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA) status
Variable | n/nb | All patients, n = 566 | Non-CAPA patients, n = 537 | CAPA patients, n = 29 | p | |
|---|---|---|---|---|---|---|
Invasive MV | 242 (43) | 220 (41) | 22 (76) | 0.0002 | ||
Prone positioning | 171 (32) | 153 (30) | 18 (64) | 0.0002 | ||
MV duration, days | 207/21 | 12 [5–22] | 10 [5–20] | 28 [17–34] | 0.0001 | |
Ventilator-free days at D28 | 25 [0–28] | 26 [0–28] | 0 [0–15] | 0.0004 | ||
ECMO support | 32 (6) | 29 (5) | 3 (10) | 0.2 | ||
Duration of ECMO, days | 25/3 | 27 [10–55] | 29 [10–62] | 19 [15–20] | 0.4 | |
Vasopressor support | 218 (39) | 197 (37) | 21 (72) | 0.0003 | ||
Duration of vasopressors, days | 192/20 | 27 [10–55] | 29 [10–62] | 19 [15–20] | 0.4 | |
Renal replacement therapy | 69 (12) | 60 (11) | 9 (31) | 0.001 | ||
Ventilator-acquired pneumonia (among IMV)a | 126 (52) | 108 (49) | 18 (82) | 0.003 | ||
Time from IMV to VAP first episode, days | 6 [2–10] | 6 [2–9] | 11 [6–20] | 0.003 | ||
Number of VAP episodes | Median (IQR) | 1 [0–1] | 1 [0–1] | 1 [1, 2] | 0.007 | |
0 | 116 (48) | 112 (51) | 4 (18) | 0.01 | ||
1 | 66 (27) | 56 (26) | 10 (45) | |||
2 | 40 (17) | 35 (16) | 5 (23) | |||
3 | 19 (8) | 16 (7) | 3 (14) | |||
Dexamethasone | 415 (83) | 392 (83) | 23 (82) | 0.9 | ||
Tocilizumab | 165 (33) | 153 (33) | 9 (33) | 0.9 | ||
Monoclonal antibodies | 74 (15) | 67 (14) | 7 (25) | 0.1 | ||
Day-28 mortality | 161 (29) | 151 (29) | 10 (34) | 0.5 | ||
Duration of ICU stay, days | 522/29 | 9 [4–18] | 8 [4–17] | 28 [16–44] | < 0.0001 | |